NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

CollPlant Biotechnologies logo
$4.74 +0.10 (+2.16%)
Closing price 11/12/2026 07:59 PM Eastern
Extended Trading
$4.74 0.00 (0.00%)
As of 11/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

Advanced

Key Stats

Today's Range
$4.05
▼
$4.64
50-Day Range
$3.39
▼
$4.74
52-Week Range
$2.64
▼
$22.50
Volume
437,744 shs
Average Volume
56,370 shs
Market Capitalization
$8.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00
Consensus Rating
Reduce

Company Overview

CollPlant Biotechnologies is an Israel-based regenerative medicine company developing products and technologies based on recombinant human collagen (rhCollagen). Its proprietary production process uses genetically engineered plants to produce human collagen, offering an alternative to collagen sourced from animals or human tissue.

The company’s rhCollagen platform is intended for applications including tissue repair, 3D bioprinting and medical aesthetics. Its development work includes bioinks and other collagen-based materials designed for use in regenerative medicine and tissue engineering.

Founded in 2004, CollPlant has pursued collaborations to develop bioprinted tissues and other medical applications. The company is headquartered in Israel and works with partners to advance its technology and products.

AI Generated. May Contain Errors.

CollPlant Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

CLGN MarketRank™: 
2.51589825119 of 5 stars

CollPlant Biotechnologies scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CollPlant Biotechnologies has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    CollPlant Biotechnologies has a consensus price target of $120.00, representing about 2,431.6% upside from its current price of $4.74.

  • Amount of Analyst Coverage

    CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

  • Read more about CollPlant Biotechnologies' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CollPlant Biotechnologies is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CollPlant Biotechnologies is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CollPlant Biotechnologies has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about CollPlant Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    2.08% of the float of CollPlant Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CollPlant Biotechnologies has recently decreased by 32.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CollPlant Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    CollPlant Biotechnologies does not have a long track record of dividend growth.

  • News Sentiment

    CollPlant Biotechnologies has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CollPlant Biotechnologies this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.60% of the stock of CollPlant Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    21.69% of the stock of CollPlant Biotechnologies is held by institutions.

  • Read more about CollPlant Biotechnologies' insider trading history.
Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLGN Stock News Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
LightSolver and Why AI May Outrun the GPU (NASDAQ: CLGN)
See More Headlines

CLGN Stock Analysis - Frequently Asked Questions

CollPlant Biotechnologies' stock was trading at $14.00 at the start of the year. Since then, CLGN stock has decreased by 66.1% and is now trading at $4.74.

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) posted its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.89) EPS for the quarter, topping analysts' consensus estimates of ($2.45) by $0.56. The business had revenue of $108 thousand for the quarter, compared to analyst estimates of $480 thousand. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 298.21% and a negative net margin of 678.37%.

Shares of CollPlant Biotechnologies reverse split on Friday, September 4th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoFi Technologies (SOFI), SoundHound AI (SOUN), Tesla (TSLA), Vertex Pharmaceuticals (VRTX) and ChargePoint (CHPT).

Company Calendar

Last Earnings
9/30/2026
Today
11/16/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLGN
CIK
1631487
Employees
70
Year Founded
1981

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+2,431.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.49 million
Net Margins
-678.37%
Pretax Margin
-490.32%
Return on Equity
-298.21%
Return on Assets
-167.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.57
Quick Ratio
1.35

Sales & Book Value

Annual Sales
$2.37 million
Price / Sales
3.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.76 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
1,890,000
Free Float
1,709,000
Market Cap
$8.96 million
Optionable
Optionable
Beta
1.66

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CLGN) was last updated on 11/12/2026 by MarketBeat.com Staff.
From Our Partners